Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Fine-Chemical Producers Make Targeted Investments

Contract API manufacturers proceed with select investment in capacity and service additions.
Apr 2, 2013

Contract API manufacturers proceed with select investment in capacity and service additions.

The Weaknesses and Strengths of the Global API Market

Supply-demand fundamentals show strong growth for generic APIs as gains in innovator APIs lag.
Mar 6, 2013

Supply-demand fundamentals show strong growth for generic APIs as gains in innovator APIs lag.

Fine-Chemical Producers Outline Expansion Plans at Informex

Contract API manufacturers and fine-chemical producers proceed with select investment in capacity and service additions.
Mar 6, 2013

Contract API manufacturers and fine-chemical producers proceed with select investment in capacity and service additions.

Pharma Industry Outlines Opportunity for Incremental Innovation to Improve Global Health

Incremental innovation advances medicines by expanding therapeutic classes, increasing the number of available dosing options, discovering new physiological interactions of known medicines, and improving other properties of existing medicines.
Mar 6, 2013

Incremental innovation advances medicines by expanding therapeutic classes, increasing the number of available dosing options, discovering new physiological interactions of known medicines, and improving other properties of existing medicines

Advancing analytical testing and instrumentation for biopharmaceuticals

Instrument manufacturers and testing service providers are offering improved tools to biologic charaterization.
Mar 2, 2013

Instrument manufacturers and testing service providers are offering improved tools to biologic charaterization.

Advances in PAT for Parenteral Drug Manufacturing

Applying quality-by-design and process analytical technology facilitates process understanding and control of various operations in lyophilization.
Mar 2, 2013

Applying quality-by-design and process analytical technology facilitates process understanding and control of various operations in lyophilization.

Navigating the Global Manufacturing Supply Chain

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.
Mar 2, 2013

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.

Quality by Design in Excipients

Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.
Mar 1, 2013

Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.

Optimizing Facilities Management in the Pharma Industry

In the era of manufacturing capacity rationalizaton, tighter return on assets, and re-alignment of manufacturing assets to meet changing product demand, strategies for cost-effectively managing manufacturing and other facilities become ever-more crucial. A Q&A with UMS Advisory.
Feb 6, 2013

In the era of manufacturing capacity rationalizaton, tighter return on assets, and re-alignment of manufacturing assets to meet changing product demand, strategies for cost-effectively managing manufacturing and other facilities become ever-more crucial. A Q&A with UMS Advisory.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here